Influence of Telaprevir Exposure on the Severe Anemia Induced by Ribavirin/Pegylated Interferon/Telaprevir Tri-therapy in HCV Infected Patients

Trial Profile

Influence of Telaprevir Exposure on the Severe Anemia Induced by Ribavirin/Pegylated Interferon/Telaprevir Tri-therapy in HCV Infected Patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Jan 2017 Status changed from recruiting to discontinued.
    • 04 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top